Stiefel acquires ABR Invent and ABR Development

Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in France.

Atlean dermal filler is currently commercialized in France and Italy and distribution and manufacturing agreements for the product will remain in place throughout Europe. All sales representatives formerly employed by ABR Development will now become employees of Stiefel Laboratories.

Over the next 18 months, Stiefel plans to launch Atlean dermal filler in multiple areas, including parts of Europe, Asia Pacific, Latin America and the Caribbean. The company will continue clinical development of Atlean dermal filler in order to expeditiously submit the product for approval from the FDA and other regulatory bodies around the world. Stiefel also expects to develop other products from the ABR portfolio.

Atlean dermal filler uses a combination of tricalcium phosphate particles (Beta-TCP) suspended in a hyaluronic acid gel. The injectable product is recommended for sculpting and remodelling the face.